We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angel Biotech | LSE:ABH | London | Ordinary Share | GB00B0HZJ337 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.05 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMABH
RNS Number : 4340B
Angel Biotechnology Holdings Plc
17 April 2012
17(th) April 2012
Angel Biotechnology Holdings plc
("Angel" or "the Company")
Angel Biotechnology Holdings and TransGenRx Inc. sign contract for
development of a recombinant interferon product.
Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce that it has agreed a contract with TransGenRx Inc. (Baton Rouge, USA) for the development and scale up of a recombinant interferon product. The purpose of the contract is to attain acceptable expression levels on which to establish a GMP manufacturing process, which would then be conducted by Angel. This development work for TransGenRx will take place at Angel's GMP facility at Cramlington and will have a value in excess of GBP800,000.
Dr Stewart White, Acting CEO and Commercial Director, Angel Biotechnology Holdings, said:
"This contract demonstrates the confidence which TransGenRx has in the ability of Angel to develop and manufacture complex proteins and reinforces the board's decision to invest in this additional capacity. We look forward to taking this product through to GMP manufacturing in our Cramlington facility and to a long and fruitful relationship between our respective companies."
Dr Richard Cooper, CSO, "TransGenRx Inc.", said:
"The development and production of this interferon product is key to the future of TransGenRx, hence the reason we have entrusted its delivery to the team at Angel. We are confident this will be the first of a number of projects that we would like to progress with Angel".
For further information:
Angel Biotechnology Holdings plc
Lorna Peers, Finance Director +44 (0) 131 445 6077
Stewart White, Acting CEO/Commercial Director www.angelbio.com
Grant Thornton, Corporate Finance
Colin Aaronson / Melanie Frean / Elliot Berg +44 (0) 20 7383 5100
Hybridan LLP (Broker)
Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350
Media enquiries:
The Communications Portfolio Ltd
Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029
ariane.comstive@communications-portfolio.co.uk
Notes to Editors:
Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.
Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines and Healthcare products Regulatory Agency (MHRA).
Its customers range from early-stage biotechnology companies including ReNeuron plc and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.
Angel has two facilities: Pentlands Science Park near Edinburgh where it employs 38 people, and a site in Cramlington, near Newcastle-upon-Tyne, which is expected to employ up to 10 people by the end of 2012.
More information is available at www.angelbio.com .
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTGGUGWCUPPGAQ
1 Year Angel Biotechnology Chart |
1 Month Angel Biotechnology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions